NCT00958412

Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

A Randomized, Double-blind Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Premenopausal Women With Symptomatic Endometriosis-extension Study

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Repros Therapeutics Inc. · Industry
• Sex: Female
• Age: 18 Years – 48 Years
• Healthy volunteers: Not accepted

Summary

ZPE-201 Extension of treatment

Detailed description

This is an extension of the phase II, three-arm, parallel design, dose-ranging, placebo-controlled, randomized, double-blind, multicenter study in which placebo or one (1) of two (2) dose levels of Proellex® was administered once-daily for four (4) months.

Conditions

• Endometriosis

Interventions

Type	Name	Description
DRUG	Proellex®	one (1) 25 mg capsule daily

Timeline

• Start date: 2009-02-28
• Primary completion: 2009-08-31
• Completion: 2009-08-31
• First posted: 2009-08-13
• Last updated: 2019-02-12
• Results posted: 2019-02-12

Locations

8 sites across 1 country: United States